Post-pandemic SARS-CoV-2 seroprevalence and population immunity in Conakry, Guinea, 2024

Résumé fourni par la source

Since May 2023, COVID-19 is no longer a Public Health Emergency of International Concern. However, it remains an infection that requires monitoring, especially in the post-emergency context where testing and preventative measures have been abandoned by the population. The objective of this study was therefore to measure the seroprevalence of antibodies against SARS-CoV-2 in Conakry in the post-health emergency period and to identify the associated factors. In January 2024, we conducted a population-based, age-stratified seroprevalence survey in Conakry. We collected demographic and epidemiological information, as well as dried blood spot samples, and tested them for immunoglobulin G (IgG) antibodies to SARS-CoV-2 recombinant nucleocapsid and spike proteins using Luminex technology. Overall, 1018 individuals with a median age of 18 years (IQR: 10–37 years) from 180 households participated in the survey. The overall weighted and age-standardized SARS-CoV-2 IgG seroprevalence against spike and nucleocapsid proteins was 88.9% (95% CI: 80.8–93.9). People with secondary education (AOR = 4.10, 95% CI: 1.46–11.51) and those who had been vaccinated (AOR = 2.53, 95% CI: 1.26–5.10) were significantly more likely to have SARS-CoV-2 antibodies. High SARS-CoV-2 seroprevalence in Conakry indicates widespread community exposure through infection and/or vaccination. Secondary education and vaccination were associated with antibody positivity. Despite strong population immunity, continued surveillance, improved vaccine access, and strengthened public health communication remain essential to address ongoing viral circulation and potential waning immunity in Guinea.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.